Validation of (array-based) FOS, TGFβR2, TPX2, LAPTM4B, PIEZO2, ANGPT1, CFH, CD109 and HLTF transcripts by differential expression analysis in >1% and not detected %BCR-ABL 23 Imatinib-treated CML cases using beta actin and 18s ribosomal house-keeping gene as reference. This evidence concerns the gene LAPTM4B and chronic myelogenous leukemia, BCR-ABL1 positive.